The relationship between weight gain during chemotherapy and outcomes in patients with advanced non‐small cell lung cancer
Background This post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non‐small cell lung cancer (NSCLC) receiving first‐line platinum‐based chemotherapy. Methods Data were pooled from the control arms of three phase I...
Saved in:
| Published in | Journal of cachexia, sarcopenia and muscle Vol. 15; no. 3; pp. 1030 - 1040 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Germany
John Wiley & Sons, Inc
01.06.2024
John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2190-5991 2190-6009 2190-6009 |
| DOI | 10.1002/jcsm.13426 |
Cover
| Abstract | Background
This post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non‐small cell lung cancer (NSCLC) receiving first‐line platinum‐based chemotherapy.
Methods
Data were pooled from the control arms of three phase III clinical studies (NCT00596830, NCT00254891, and NCT00254904), and the maximum weight gain in the first 3 months from treatment initiation was categorised as >0%, >2.5%, and >5.0%. Cox proportional hazard modelling of OS was used to estimate hazard ratios (HRs) for each category, including baseline covariates, time to weight gain, and time to confirmed objective response (RECIST Version 1.0).
Results
Of 1030 patients with advanced NSCLC (IIIB 11.5% and IV 88.5%), 453 (44.0%), 252 (24.5%), and 120 (11.7%) experienced weight gain from baseline of >0%, >2.5%, and >5.0%, respectively. The median time to weight gain was 23 (>0%), 43 (>2.5%), and 45 (>5.0%) days. After adjusting for a time‐dependent confirmed objective response, the risk of death was reduced for patients with any weight gain (>0% vs. ≤0% [HR 0.71; 95% confidence interval—CI 0.61, 0.82], >2.5% vs. ≤2.5% [HR 0.76; 95% CI 0.64, 0.91] and >5.0% vs. ≤5.0% [HR 0.77; 95% CI 0.60, 0.99]). The median OS was 13.5 versus 8.6 months (weight gain >0% vs. ≤0%), 14.4 versus 9.4 months (weight gain >2.5% vs. ≤2.5%), and 13.4 versus 10.2 months (weight gain >5.0% vs. ≤5.0%).
Conclusions
Weight gain during treatment was associated with a reduced risk of death, independent of tumour response. The survival benefit was comparable for weight gain >0%, >2.5%, and >5.0%, suggesting that any weight gain may be an early predictor of survival with implications for the design of interventional cancer cachexia studies. |
|---|---|
| AbstractList | Background
This post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non‐small cell lung cancer (NSCLC) receiving first‐line platinum‐based chemotherapy.
Methods
Data were pooled from the control arms of three phase III clinical studies (NCT00596830, NCT00254891, and NCT00254904), and the maximum weight gain in the first 3 months from treatment initiation was categorised as >0%, >2.5%, and >5.0%. Cox proportional hazard modelling of OS was used to estimate hazard ratios (HRs) for each category, including baseline covariates, time to weight gain, and time to confirmed objective response (RECIST Version 1.0).
Results
Of 1030 patients with advanced NSCLC (IIIB 11.5% and IV 88.5%), 453 (44.0%), 252 (24.5%), and 120 (11.7%) experienced weight gain from baseline of >0%, >2.5%, and >5.0%, respectively. The median time to weight gain was 23 (>0%), 43 (>2.5%), and 45 (>5.0%) days. After adjusting for a time‐dependent confirmed objective response, the risk of death was reduced for patients with any weight gain (>0% vs. ≤0% [HR 0.71; 95% confidence interval—CI 0.61, 0.82], >2.5% vs. ≤2.5% [HR 0.76; 95% CI 0.64, 0.91] and >5.0% vs. ≤5.0% [HR 0.77; 95% CI 0.60, 0.99]). The median OS was 13.5 versus 8.6 months (weight gain >0% vs. ≤0%), 14.4 versus 9.4 months (weight gain >2.5% vs. ≤2.5%), and 13.4 versus 10.2 months (weight gain >5.0% vs. ≤5.0%).
Conclusions
Weight gain during treatment was associated with a reduced risk of death, independent of tumour response. The survival benefit was comparable for weight gain >0%, >2.5%, and >5.0%, suggesting that any weight gain may be an early predictor of survival with implications for the design of interventional cancer cachexia studies. This post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy. Data were pooled from the control arms of three phase III clinical studies (NCT00596830, NCT00254891, and NCT00254904), and the maximum weight gain in the first 3 months from treatment initiation was categorised as >0%, >2.5%, and >5.0%. Cox proportional hazard modelling of OS was used to estimate hazard ratios (HRs) for each category, including baseline covariates, time to weight gain, and time to confirmed objective response (RECIST Version 1.0). Of 1030 patients with advanced NSCLC (IIIB 11.5% and IV 88.5%), 453 (44.0%), 252 (24.5%), and 120 (11.7%) experienced weight gain from baseline of >0%, >2.5%, and >5.0%, respectively. The median time to weight gain was 23 (>0%), 43 (>2.5%), and 45 (>5.0%) days. After adjusting for a time-dependent confirmed objective response, the risk of death was reduced for patients with any weight gain (>0% vs. ≤0% [HR 0.71; 95% confidence interval-CI 0.61, 0.82], >2.5% vs. ≤2.5% [HR 0.76; 95% CI 0.64, 0.91] and >5.0% vs. ≤5.0% [HR 0.77; 95% CI 0.60, 0.99]). The median OS was 13.5 versus 8.6 months (weight gain >0% vs. ≤0%), 14.4 versus 9.4 months (weight gain >2.5% vs. ≤2.5%), and 13.4 versus 10.2 months (weight gain >5.0% vs. ≤5.0%). Weight gain during treatment was associated with a reduced risk of death, independent of tumour response. The survival benefit was comparable for weight gain >0%, >2.5%, and >5.0%, suggesting that any weight gain may be an early predictor of survival with implications for the design of interventional cancer cachexia studies. BackgroundThis post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy.MethodsData were pooled from the control arms of three phase III clinical studies (NCT00596830, NCT00254891, and NCT00254904), and the maximum weight gain in the first 3 months from treatment initiation was categorised as >0%, >2.5%, and >5.0%. Cox proportional hazard modelling of OS was used to estimate hazard ratios (HRs) for each category, including baseline covariates, time to weight gain, and time to confirmed objective response (RECIST Version 1.0).ResultsOf 1030 patients with advanced NSCLC (IIIB 11.5% and IV 88.5%), 453 (44.0%), 252 (24.5%), and 120 (11.7%) experienced weight gain from baseline of >0%, >2.5%, and >5.0%, respectively. The median time to weight gain was 23 (>0%), 43 (>2.5%), and 45 (>5.0%) days. After adjusting for a time-dependent confirmed objective response, the risk of death was reduced for patients with any weight gain (>0% vs. ≤0% [HR 0.71; 95% confidence interval—CI 0.61, 0.82], >2.5% vs. ≤2.5% [HR 0.76; 95% CI 0.64, 0.91] and >5.0% vs. ≤5.0% [HR 0.77; 95% CI 0.60, 0.99]). The median OS was 13.5 versus 8.6 months (weight gain >0% vs. ≤0%), 14.4 versus 9.4 months (weight gain >2.5% vs. ≤2.5%), and 13.4 versus 10.2 months (weight gain >5.0% vs. ≤5.0%).ConclusionsWeight gain during treatment was associated with a reduced risk of death, independent of tumour response. The survival benefit was comparable for weight gain >0%, >2.5%, and >5.0%, suggesting that any weight gain may be an early predictor of survival with implications for the design of interventional cancer cachexia studies. This post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy.BACKGROUNDThis post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy.Data were pooled from the control arms of three phase III clinical studies (NCT00596830, NCT00254891, and NCT00254904), and the maximum weight gain in the first 3 months from treatment initiation was categorised as >0%, >2.5%, and >5.0%. Cox proportional hazard modelling of OS was used to estimate hazard ratios (HRs) for each category, including baseline covariates, time to weight gain, and time to confirmed objective response (RECIST Version 1.0).METHODSData were pooled from the control arms of three phase III clinical studies (NCT00596830, NCT00254891, and NCT00254904), and the maximum weight gain in the first 3 months from treatment initiation was categorised as >0%, >2.5%, and >5.0%. Cox proportional hazard modelling of OS was used to estimate hazard ratios (HRs) for each category, including baseline covariates, time to weight gain, and time to confirmed objective response (RECIST Version 1.0).Of 1030 patients with advanced NSCLC (IIIB 11.5% and IV 88.5%), 453 (44.0%), 252 (24.5%), and 120 (11.7%) experienced weight gain from baseline of >0%, >2.5%, and >5.0%, respectively. The median time to weight gain was 23 (>0%), 43 (>2.5%), and 45 (>5.0%) days. After adjusting for a time-dependent confirmed objective response, the risk of death was reduced for patients with any weight gain (>0% vs. ≤0% [HR 0.71; 95% confidence interval-CI 0.61, 0.82], >2.5% vs. ≤2.5% [HR 0.76; 95% CI 0.64, 0.91] and >5.0% vs. ≤5.0% [HR 0.77; 95% CI 0.60, 0.99]). The median OS was 13.5 versus 8.6 months (weight gain >0% vs. ≤0%), 14.4 versus 9.4 months (weight gain >2.5% vs. ≤2.5%), and 13.4 versus 10.2 months (weight gain >5.0% vs. ≤5.0%).RESULTSOf 1030 patients with advanced NSCLC (IIIB 11.5% and IV 88.5%), 453 (44.0%), 252 (24.5%), and 120 (11.7%) experienced weight gain from baseline of >0%, >2.5%, and >5.0%, respectively. The median time to weight gain was 23 (>0%), 43 (>2.5%), and 45 (>5.0%) days. After adjusting for a time-dependent confirmed objective response, the risk of death was reduced for patients with any weight gain (>0% vs. ≤0% [HR 0.71; 95% confidence interval-CI 0.61, 0.82], >2.5% vs. ≤2.5% [HR 0.76; 95% CI 0.64, 0.91] and >5.0% vs. ≤5.0% [HR 0.77; 95% CI 0.60, 0.99]). The median OS was 13.5 versus 8.6 months (weight gain >0% vs. ≤0%), 14.4 versus 9.4 months (weight gain >2.5% vs. ≤2.5%), and 13.4 versus 10.2 months (weight gain >5.0% vs. ≤5.0%).Weight gain during treatment was associated with a reduced risk of death, independent of tumour response. The survival benefit was comparable for weight gain >0%, >2.5%, and >5.0%, suggesting that any weight gain may be an early predictor of survival with implications for the design of interventional cancer cachexia studies.CONCLUSIONSWeight gain during treatment was associated with a reduced risk of death, independent of tumour response. The survival benefit was comparable for weight gain >0%, >2.5%, and >5.0%, suggesting that any weight gain may be an early predictor of survival with implications for the design of interventional cancer cachexia studies. Abstract Background This post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non‐small cell lung cancer (NSCLC) receiving first‐line platinum‐based chemotherapy. Methods Data were pooled from the control arms of three phase III clinical studies (NCT00596830, NCT00254891, and NCT00254904), and the maximum weight gain in the first 3 months from treatment initiation was categorised as >0%, >2.5%, and >5.0%. Cox proportional hazard modelling of OS was used to estimate hazard ratios (HRs) for each category, including baseline covariates, time to weight gain, and time to confirmed objective response (RECIST Version 1.0). Results Of 1030 patients with advanced NSCLC (IIIB 11.5% and IV 88.5%), 453 (44.0%), 252 (24.5%), and 120 (11.7%) experienced weight gain from baseline of >0%, >2.5%, and >5.0%, respectively. The median time to weight gain was 23 (>0%), 43 (>2.5%), and 45 (>5.0%) days. After adjusting for a time‐dependent confirmed objective response, the risk of death was reduced for patients with any weight gain (>0% vs. ≤0% [HR 0.71; 95% confidence interval—CI 0.61, 0.82], >2.5% vs. ≤2.5% [HR 0.76; 95% CI 0.64, 0.91] and >5.0% vs. ≤5.0% [HR 0.77; 95% CI 0.60, 0.99]). The median OS was 13.5 versus 8.6 months (weight gain >0% vs. ≤0%), 14.4 versus 9.4 months (weight gain >2.5% vs. ≤2.5%), and 13.4 versus 10.2 months (weight gain >5.0% vs. ≤5.0%). Conclusions Weight gain during treatment was associated with a reduced risk of death, independent of tumour response. The survival benefit was comparable for weight gain >0%, >2.5%, and >5.0%, suggesting that any weight gain may be an early predictor of survival with implications for the design of interventional cancer cachexia studies. |
| Author | Fintelmann, Florian J. Yang, Ruoyong Whalen, Ed Roeland, Eric J. Bonomi, Philip D. Hilton, Fiona Calle, Roberto A. Tarasenko, Lisa |
| AuthorAffiliation | 6 Rush University Medical Center Chicago IL USA 1 Knight Cancer Institute Oregon Health and Science University Portland OR USA 4 Pfizer Inc. New York NY USA 3 Pfizer Inc. Groton CT USA 5 Pfizer Worldwide Research and Development Cambridge MA USA 2 Department of Radiology Massachusetts General Hospital Boston MA USA |
| AuthorAffiliation_xml | – name: 1 Knight Cancer Institute Oregon Health and Science University Portland OR USA – name: 5 Pfizer Worldwide Research and Development Cambridge MA USA – name: 2 Department of Radiology Massachusetts General Hospital Boston MA USA – name: 3 Pfizer Inc. Groton CT USA – name: 4 Pfizer Inc. New York NY USA – name: 6 Rush University Medical Center Chicago IL USA |
| Author_xml | – sequence: 1 givenname: Eric J. orcidid: 0000-0002-3674-3573 surname: Roeland fullname: Roeland, Eric J. email: roeland@ohsu.edu organization: Oregon Health and Science University – sequence: 2 givenname: Florian J. surname: Fintelmann fullname: Fintelmann, Florian J. organization: Massachusetts General Hospital – sequence: 3 givenname: Fiona surname: Hilton fullname: Hilton, Fiona organization: Pfizer Inc – sequence: 4 givenname: Ruoyong surname: Yang fullname: Yang, Ruoyong organization: Pfizer Inc – sequence: 5 givenname: Ed surname: Whalen fullname: Whalen, Ed organization: Pfizer Inc – sequence: 6 givenname: Lisa surname: Tarasenko fullname: Tarasenko, Lisa organization: Pfizer Inc – sequence: 7 givenname: Roberto A. surname: Calle fullname: Calle, Roberto A. organization: Pfizer Worldwide Research and Development – sequence: 8 givenname: Philip D. surname: Bonomi fullname: Bonomi, Philip D. organization: Rush University Medical Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38468440$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAQgCNUREvphQdAlrggpC3jxHHiE0IVP0VFHChnyz-zG68Se7GTrlbiwCPwjDwJ3p8iWiF8sC37m0_j8TwujnzwWBRPKZxTgPLV0qThnFas5A-Kk5IKmHEAcXTY10LQ4-IspSXkwTjlNTwqjquW8ZYxOCm-X3dIIvZqdMGnzq2IxnGN6Mka3aIbyUI5T-wUnV8Q0-EQxg6jWm2I8paEaTRhwEQys8oK9GMiazd2RNkb5Q1aktP99eNnGlTfE4N56qetaXsZnxQP56pPeHZYT4uv795eX3yYXX1-f3nx5mpm6rbkM67m2gJjqITgXNTc5nOotW0102Zecd6YRtdNxZnR84oKpSqjSkNLKAVgW50Wl3uvDWopV9ENKm5kUE7uDkJcSBVHZ3qUAi2DWujailwuU6pGaVsxAaBZjQKy6_XetZr0gNbkJ0fV35HevfGuk4twIymlNWsYz4YXB0MM3yZMoxxc2pZGeQxTkmV-IeXQtiKjz--hyzBFn2slK-CsqRrgZaae_Z3Sn1xufzkDsAdMDClFnEvjxt2P5wxdLynIbS_JbS_JXS_lkJf3Qm6t_4TpHl67Hjf_IeXHiy-f9jG_Aftf3EI |
| CitedBy_id | crossref_primary_10_3390_cancers16132364 crossref_primary_10_1002_jcsm_13694 |
| Cites_doi | 10.1200/JOP.2016.016832 10.1016/j.ijrobp.2010.06.059 10.1002/jcsm.12910 10.1093/jnci/92.3.205 10.1016/j.esmoop.2021.100092 10.1016/S1470-2045(15)00558-6 10.1200/JCO.20.00611 10.3390/ijms22168491 10.1007/s00520-016-3156-8 10.3109/0284186X.2014.953259 10.1093/annonc/mdw211 10.1016/j.cllc.2012.10.009 10.2307/2530286 10.1002/jcsm.12899 10.1002/jcsm.13095 10.21037/atm.2017.03.20 10.1016/S1470-2045(10)70218-7 10.1097/00000421-198212000-00014 10.1080/13543784.2019.1646727 10.1016/S0149-2918(05)80001-3 10.1016/j.ijrobp.2013.07.033 10.1002/jcsm.12402 10.1089/jpm.2014.0331 10.21037/atm.2016.09.33 10.1007/s00520-019-05259-1 10.1002/jcsm.12625 |
| ContentType | Journal Article |
| Copyright | 2024 Pfizer Inc. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC. 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2024 Pfizer Inc. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC. – notice: 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1002/jcsm.13426 |
| DatabaseName | Wiley Online Library Open Access (Activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access (Activated by CARLI) url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 7X7 name: Health & Medical Collection (ProQuest) url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Weight gain during NSCLC treatment as an indicator of benefit |
| EISSN | 2190-6009 |
| EndPage | 1040 |
| ExternalDocumentID | oai_doaj_org_article_9ed4059b5d9046c2a7abd34900b45e90 PMC11154746 38468440 10_1002_jcsm_13426 JCSM13426 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: Pfizer |
| GroupedDBID | --- 0R~ 1OC 24P 2VQ 4.4 40G 53G 5VS 7X7 8FI 8FJ AAFWJ AAKDD AAMMB AAZKR ABUWG ACCMX ACXQS ADBBV ADKYN ADRAZ ADZMN AEFGJ AENEX AFKRA AFPKN AGXDD AHBYD AHSBF AIDQK AIDYY ALMA_UNASSIGNED_HOLDINGS ALUQN AMKLP AOIJS AVUZU AZFZN BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU DIK EBS EJD EMOBN FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH ITC KQ8 M48 O9- OK1 PHGZM PHGZT PIMPY PQQKQ PROAC PUEGO RPM RSV SMD SOJ U2A UKHRP WIN ZOVNA AAHHS AAYXX ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE ALIPV CITATION CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c5826-6afbd044ea9966956dc5805bd8b4bcf3667c7b57364cbf319aa3ca2c120290e83 |
| IEDL.DBID | M48 |
| ISSN | 2190-5991 2190-6009 |
| IngestDate | Wed Aug 27 01:20:37 EDT 2025 Thu Aug 21 18:33:48 EDT 2025 Thu Sep 04 19:27:13 EDT 2025 Fri Jul 25 04:20:39 EDT 2025 Mon Jul 21 06:00:11 EDT 2025 Tue Jul 01 02:51:36 EDT 2025 Thu Apr 24 23:06:05 EDT 2025 Sun Sep 21 06:15:14 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | weight non‐small cell lung cancer cachexia survival weight gain |
| Language | English |
| License | Attribution 2024 Pfizer Inc. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5826-6afbd044ea9966956dc5805bd8b4bcf3667c7b57364cbf319aa3ca2c120290e83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-3674-3573 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1002/jcsm.13426 |
| PMID | 38468440 |
| PQID | 3064737062 |
| PQPubID | 4370305 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9ed4059b5d9046c2a7abd34900b45e90 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11154746 proquest_miscellaneous_2956160889 proquest_journals_3064737062 pubmed_primary_38468440 crossref_citationtrail_10_1002_jcsm_13426 crossref_primary_10_1002_jcsm_13426 wiley_primary_10_1002_jcsm_13426_JCSM13426 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | June 2024 |
| PublicationDateYYYYMMDD | 2024-06-01 |
| PublicationDate_xml | – month: 06 year: 2024 text: June 2024 |
| PublicationDecade | 2020 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany – name: Heidelberg – name: Hoboken |
| PublicationTitle | Journal of cachexia, sarcopenia and muscle |
| PublicationTitleAlternate | J Cachexia Sarcopenia Muscle |
| PublicationYear | 2024 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | 2017; 5 2021; 6 1980; 69 1982; 38 2021; 22 2015; 18 2013; 87 2019; 10 2011; 81 2015; 54 2020; 38 2000; 92 2011; 12 2020; 11 2016; 17 2016; 12 2016; 4 2013; 14 2021; 12 1982; 5 2019; 28 2020; 28 2022; 13 2016; 27 2016; 24 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_14_1 e_1_2_8_15_1 e_1_2_8_16_1 e_1_2_8_10_1 e_1_2_8_11_1 e_1_2_8_12_1 |
| References_xml | – volume: 81 start-page: 985 year: 2011 end-page: 991 article-title: Weight gain in advanced non‐small‐cell lung cancer patients during treatment with split‐course concurrent chemoradiotherapy is associated with superior survival publication-title: Int J Radiat Oncol Biol Phys – volume: 5 start-page: 649 year: 1982 end-page: 655 article-title: Toxicity and response criteria of the Eastern Cooperative Oncology Group publication-title: Am J Clin Oncol – volume: 12 start-page: 1163 year: 2016 end-page: 1171 article-title: Cancer cachexia: beyond weight loss publication-title: J Oncol Pract – volume: 28 start-page: 733 year: 2019 end-page: 740 article-title: Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials publication-title: Expert Opin Investig Drugs – volume: 12 start-page: 2259 year: 2021 end-page: 2261 article-title: Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021 publication-title: J Cachexia Sarcopenia Muscle – volume: 27 start-page: 1612 year: 2016 end-page: 1619 article-title: Relationship between efficacy outcomes and weight gain during treatment of advanced, non‐squamous, non‐small‐cell lung cancer patients publication-title: Ann Oncol – volume: 18 start-page: 382 year: 2015 end-page: 385 article-title: Lack of documentation of evidence‐based prognostication in cancer patients by inpatient palliative care consultants publication-title: J Palliat Med – volume: 12 start-page: 489 year: 2011 end-page: 495 article-title: Definition and classification of cancer cachexia: an international consensus publication-title: Lancet Oncol – volume: 10 start-page: 22 year: 2019 end-page: 34 article-title: Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review publication-title: J Cachexia Sarcopenia Muscle – volume: 4 start-page: 381 year: 2016 article-title: Weight gain as a surrogate marker of longer survival in advanced non‐small cell lung cancer patients publication-title: Ann Transl Med – volume: 22 year: 2021 article-title: Cancer cachexia: its mechanism and clinical significance publication-title: Int J Mol Sci – volume: 11 start-page: 1501 year: 2020 end-page: 1508 article-title: Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients publication-title: J Cachexia Sarcopenia Muscle – volume: 69 start-page: 491 year: 1980 end-page: 497 article-title: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group publication-title: Am J Med – volume: 5 start-page: 152 year: 2017 article-title: Practical and theoretical implications of weight gain in advanced non‐small cell lung cancer patients publication-title: Ann Transl Med – volume: 13 start-page: 2650 year: 2022 end-page: 2660 article-title: Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer publication-title: J Cachexia Sarcopenia Muscle – volume: 14 start-page: 370 year: 2013 end-page: 375 article-title: Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non‐small‐cell lung cancer publication-title: Clin Lung Cancer – volume: 24 start-page: 3473 year: 2016 end-page: 3480 article-title: Quality of life and survival survey of cancer cachexia in advanced non‐small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non‐small cell lung cancer study publication-title: Support Care Cancer – volume: 87 start-page: 697 year: 2013 end-page: 704 article-title: Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non‐small cell lung cancer patients: retrospective analysis of 425 patients publication-title: Int J Radiat Oncol Biol Phys – volume: 92 start-page: 205 year: 2000 end-page: 216 article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada publication-title: J Natl Cancer Inst – volume: 38 start-page: 29 year: 1982 end-page: 41 article-title: A confidence interval for the median survival time publication-title: Biometrics – volume: 28 start-page: 4373 year: 2020 end-page: 4380 article-title: Determining the prevalence and severity of cancer cachexia in advanced non‐small cell lung cancer and its relationship with chemotherapy outcomes publication-title: Support Care Cancer – volume: 38 start-page: 2438 year: 2020 end-page: 2453 article-title: Management of cancer cachexia: ASCO guideline publication-title: J Clin Oncol – volume: 13 start-page: 1418 year: 2022 end-page: 1425 article-title: Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop publication-title: J Cachexia Sarcopenia Muscle – volume: 54 start-page: 340 year: 2015 end-page: 348 article-title: Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer publication-title: Acta Oncol – volume: 17 start-page: 519 year: 2016 end-page: 531 article-title: Anamorelin in patients with non‐small‐cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double‐blind, phase 3 trials publication-title: Lancet Oncol – volume: 6 year: 2021 article-title: Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines publication-title: ESMO Open – ident: e_1_2_8_2_1 doi: 10.1200/JOP.2016.016832 – ident: e_1_2_8_16_1 doi: 10.1016/j.ijrobp.2010.06.059 – ident: e_1_2_8_23_1 doi: 10.1002/jcsm.12910 – ident: e_1_2_8_20_1 doi: 10.1093/jnci/92.3.205 – ident: e_1_2_8_7_1 doi: 10.1016/j.esmoop.2021.100092 – ident: e_1_2_8_14_1 doi: 10.1016/S1470-2045(15)00558-6 – ident: e_1_2_8_4_1 doi: 10.1200/JCO.20.00611 – ident: e_1_2_8_5_1 doi: 10.3390/ijms22168491 – ident: e_1_2_8_12_1 doi: 10.1007/s00520-016-3156-8 – ident: e_1_2_8_26_1 doi: 10.3109/0284186X.2014.953259 – ident: e_1_2_8_19_1 doi: 10.1093/annonc/mdw211 – ident: e_1_2_8_15_1 doi: 10.1016/j.cllc.2012.10.009 – ident: e_1_2_8_22_1 doi: 10.2307/2530286 – ident: e_1_2_8_27_1 doi: 10.1002/jcsm.12899 – ident: e_1_2_8_13_1 doi: 10.1002/jcsm.13095 – ident: e_1_2_8_25_1 doi: 10.21037/atm.2017.03.20 – ident: e_1_2_8_3_1 doi: 10.1016/S1470-2045(10)70218-7 – ident: e_1_2_8_21_1 doi: 10.1097/00000421-198212000-00014 – ident: e_1_2_8_9_1 doi: 10.1080/13543784.2019.1646727 – ident: e_1_2_8_10_1 doi: 10.1016/S0149-2918(05)80001-3 – ident: e_1_2_8_17_1 doi: 10.1016/j.ijrobp.2013.07.033 – ident: e_1_2_8_6_1 doi: 10.1002/jcsm.12402 – ident: e_1_2_8_8_1 doi: 10.1089/jpm.2014.0331 – ident: e_1_2_8_24_1 doi: 10.21037/atm.2016.09.33 – ident: e_1_2_8_11_1 doi: 10.1007/s00520-019-05259-1 – ident: e_1_2_8_18_1 doi: 10.1002/jcsm.12625 |
| SSID | ssj0000461650 |
| Score | 2.3512192 |
| Snippet | Background
This post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with... This post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non-small cell... BackgroundThis post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with... Abstract Background This post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients... |
| SourceID | doaj pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1030 |
| SubjectTerms | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Body mass index cachexia Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Chemotherapy Clinical trials Female Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Middle Aged Neoplasm Staging non‐small cell lung cancer Original Patients Proportional Hazards Models Response rates survival Treatment Outcome Variables weight weight gain Weight Gain - drug effects |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k1Ki4zgAlKoX3HiI1RUVaVygUq9WX6FLtrNVptdISQO_IT-xv6Sjh1vtCsquHCL7JFjz4zjGWfmG4TeKKoC5S6UhLumFMHQEs51WVJPuG1DqBqTAmQ_y-MzcXJenW-U-ooxYQM88MC4AxU82BTKVl6BK-eYqY31XChCrKiCSt46UWTDmUrfYCGpTOVZWcyVrsAKGrFJ2cF318_eUy4iosLGaZRA-2-zNP8MmNw0ZNNJdPQA3c8mJP4wTP0huhO6R-juaf5J_hj9AtHjxTrI7WJyiXMwFv6R7kHxNzPp8JCfiEFms5yE9RObzuP5aglKGHoMNBl0tcfxthavwwVwN--uf1_1MzOd4njxj6erOFLsXDxBZ0efvh4el7nIQukqcC1KaVrriQApRc8HvCUP7aSyvrHCupZLWbvaVjWXwtkWNqwx3BnmKCNMkdDwp2gHXhueI-ypqBVpaRDKieC5DV6mGrtKOFF5U6C3a2ZrlxHIYyGMqR6wk5mOgtFJMAV6PdJeDrgbt1J9jDIbKSJWdmoADdJZg_S_NKhAe2uJ67yBex0ds5rXRLICvRq7YetFtpouzFe9ZjEpWMY4sQI9GxRknAkHu64RAgZvtlRna6rbPd3kIsF704iQVAtY3LukZX9Zvz45_HKannb_BydeoHsgVTFEwu2hneViFfbB5lral2l73QCckiqX priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection (ProQuest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4k2gICO4gBRqx87DJwQVVVWpXKDS3iK_0m61myybXSH49cw4TuiKqrfItpzYMxN_Ho-_IeSd4spzYX3KhK1S6TVPYV0vUu6YMI33eaVDgOy34vhMnszyWXS49TGscvwnhh-16yz6yA8QKZeiZEX2afUzxaxReLoaU2jcJnc4IBFM3VDOysnHgmTiRUjSmuGN6Ryw0MRQmh1c2n75kQuJvApX1qRA3X8d3vw_bPIqnA3r0dEDcj8CSfp5kPxDcsu3j8jd03hU_pj8AQWg6zHU7WK-ojEki_4K3lB6ructHW4pUpDcMl7F-k1162i33cC0-J5Cm0i92lP02dIxaIC2XZv2S71YUHT-08UW-8Gq9RNydvT1x-FxGhMtpDaH7UVa6MY4JkFSuPuBHZODcpYbVxlpbCOKorSlyUtRSGsaMFqthdWZ5RnLFPOVeEr24KX-OaGOy1KxhnuprPROGO-KkGdXSStzpxPyfpzq2kYWckyGsagH_uSsRrHUQSwJeTu1XQ3cG9e2-oISm1ogX3Yo6NbndTS_WnkHyFSZ3ClQCpvpUhsnpGLMyNwrlpD9Ud51NOK-_qdyCXkzVYP54bTq1nfbvs7wYnCBsWIJeTaox_QlArBdJSV0Xu0ozs6n7ta084tA8c2RJamUMLgPQcduGH99cvj9NDy9uHkQL8k9kJcc4tz2yd5mvfWvAFFtzOtgNn8BxSAgkA priority: 102 providerName: ProQuest – databaseName: Wiley Online Library Open Access (Activated by CARLI) dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA_nCeKL-G31lIi-KNRLkzRtwBc9PI6DE0EP7i3ka-_22O0e211E8ME_wb_Rv8SZ9ONcPATfSjNt0_xmmsl05hdCXupCx0L4mDPh61xGW-Qwr6u8CEy4SYxlbVOC7Ed1cCwPT8qTLfJ2qIXp-CHGgBtaRvpeo4Fb1-5ekoae-3b-phAww1wj18GrF6jfXH4aIyxIJa7SFq0c66VL8IRGflK-e3n5xoyUiPuv8jb_Tpr805lNs9H-bXKrdyPpuw73O2QrNnfJjaP-R_k98h3gp8sh0e1sekH7hCz6NcVC6amdNrSrUaSA27wvxPpGbRPoYr2C0YgtBZmeeLWlGLGlQ8oAbRbNrx8_27mdzSgG_-lsjXfCxuV9crz_4cveQd5vtJD7EpYXubITF5gEpHD1AyumAOdZ6ULtpPMToVTlK1dWQknvJmC01gpvuS8445rFWjwg2_DY-IjQUMhKs0kRpfYyBuFiUGmfXS29LIPNyKthsI3vWchxM4yZ6fiTuUFgTAImIy9G2YuOe-NKqfeI2SiBfNnpxGJ5anrzMzoG8Ey1K4MGtfDcVtYFITVjTpZRs4zsDIib3ohbg4uzSlRM8Yw8H5vB_HBYbRMX69ZwLAxWmCuWkYedgow9EeDb1VLCzesN1dno6mZLMz1LFN8FsiRVEl7uddKyf7y_Odz7fJSOHv-P8BNyE9CTXdbbDtleLdfxKfhXK_csmdFvUaUjlg priority: 102 providerName: Wiley-Blackwell |
| Title | The relationship between weight gain during chemotherapy and outcomes in patients with advanced non‐small cell lung cancer |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcsm.13426 https://www.ncbi.nlm.nih.gov/pubmed/38468440 https://www.proquest.com/docview/3064737062 https://www.proquest.com/docview/2956160889 https://pubmed.ncbi.nlm.nih.gov/PMC11154746 https://doaj.org/article/9ed4059b5d9046c2a7abd34900b45e90 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB71IVW9IN4YSrQILiC5rL3rtX1AiFatqkqtKiBSb9a-0gYlTokTQSUO_AR-I7-E2fU6SkTEgUtkedexvfONZ2Z39huAV2VS2oRpG1Omi5hbmcRo10WcGMrUwNqskD5B9lyc9PnpZXa5AV39zjCAzdrQztWT6k9H-9-_3r5HhX8XCETfftHNeD9haGs2YduvE7kUvuDm-y8yF4nwxVpTt3M6Q59owVS6fPku7DC0xwV3UyFLZsqz-a9zQf_OpFz2cL2JOr4Ld4JvST60YLgHG7a-DztnYfX8AfxATJBpl_12PbwhIUuLfPMTpORKDmvSblwkKMxx2J11S2RtyGQ-Q3TahmCfwMbaEDeNS7o8AlJP6t8_fzVjORoRtyJARnP3T65x-hD6x0efD0_iUH0h1hnGHLGQA2UoR_G5kAjDKIPnaaZMobjSAyZErnOV5UxwrQaoyVIyLVOdpDQtqS3YI9jC29onQEzC85IOEstLza1hyhrhi--WXPPMyAhed4Nd6UBN7ipkjKqWVDmtnIwqL6MIXi763rSEHGt7HTiZLXo4Em1_YjK9qoJOVqU16K6WKjMlIkSnMpfKMF5SqnhmSxrBXifxqgNm5SK2nOVUpBG8WDSjTrphlbWdzJsqdbuFhUsgi-BxC5DFk3QAi6BYgc7Ko6621MNrz_udOOqknOPLvfEo-8f7V6eHn8780dP_v88z2EVZ8jYxbg-2ZtO5fY4u2Ez1YDPlF_ibX-Y92D44Or_42PPTGT2veX8At842XA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbhMxFLVKkYAN4k2ggBGwAGmox_Y8vEAIClX6SDe0UnauX9MGJZOQSVSVj-IbufY8aETVXXfR2HLsucf2GfvecxF6K2LhYmZcRJjJI-5UHMG-nkaxJUwXziW5Cg6yB2n_iO8Ok-Ea-tPGwni3ynZNDAu1nRp_Rr7pmXLGMpLSz7Nfkc8a5W9X2xQaNSz23PkZfLJVn3a-gX3fUbr9_XCrHzVZBSKTAJeOUlVoSzh0y1N9-Dyw8Jwk2uaaa1OwNM1MppOMpdzoAhCqFDOKmpgSKojLGbR7A93k_ooR5k82zLozHS9enoaksNRHaCfAvTpFVLr501STjzHjXsfhwh4YUgVcxm__d9O8SJ_D_rd9D91tiCv-UiPtPlpz5QN0a9BczT9EvwFweN661p2OZrhxAcNn4fQVn6hRieuoSAxImTShX-dYlRZPlwswg6sw1GmkXivsz4hx66SAy2kZVRM1HmN_2YDHS9-OL5o_QkfXYoLHaB3-1D1F2MY8E6SIHReGO8u0s2nI6yu44YlVPfS-fdXSNKrnPvnGWNZ6zVR6s8hglh5609Wd1Vofl9b66i3W1fD63OHBdH4im-kuhbPAhIVOrABQGKoypS3jghDNEydID2209pbNolHJfxDvodddMUx3_1pV6abLSlIfiJx637QeelLDo-sJAy6Zcw6N5yvAWenqakk5Og2S4rFXZco4DO5DwNgV45e7Wz8G4dezqwfxCt3uHw725f7Owd5zdAdsx2sfuw20vpgv3Qtgcwv9MkwhjI6ve87-BSx6XSk |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbtQwFLVKkSo2iDeBAkbAAqQwSezE8QIhaBn1QSskqDQ716-0g2aSYTKjqnwaX8e186Ajqu66i2IrsXOP7RP73nMRes1jbmOibRgRnYfUyjiEdT0LYxMRVVib5tI7yB5mO0d0b5SO1tCfLhbGuVV2c6KfqE2l3R75wDFlRliUJYOidYv4tj38OPsVugxS7qS1S6fRQGTfnp_B71v9YXcbbP0mSYZffmzthG2GgVCnwKvDTBbKRBSa6Gg__CoYuB-lyuSKKl2QLGOaqZSRjGpVAFqlJFomOk6ihEc2J_DcG-gmI5S6tBFsxPr9HSdknvkEsYmL1k6Bh_XqqMngp66n72NCnabDhfXQpw24jOv-77J5kUr7tXB4B91uSSz-1KDuLlqz5T20cdAe099HvwF8eN652Z2OZ7h1B8NnficWn8hxiZsISQyombZhYOdYlgZXywWYxNYY6rSyrzV2-8W4c1jAZVWG9VROJtgdPODJ0j3HFc0foKNrMcFDtA4vtY8RNjFlPCpiS7mm1hBlTeZz_HKqaWpkgN52n1roVgHdJeKYiEa7ORHOLMKbJUCv-rqzRvfj0lqfncX6Gk6r29-o5ieiHfqCWwOsmKvUcACFTiSTyhDKo0jR1PIoQJudvUU7gdTiH9wD9LIvhqHvPqssbbWsReKCkjPnpxagRw08-pYQ4JU5oDJA-QpwVpq6WlKOT728eOwUmhiFzr3zGLui_2Jv6_uBv3pydSdeoA0YreLr7uH-U3QLTEcbd7tNtL6YL-0zIHYL9dyPIIyOr3vI_gVgI2Fc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+relationship+between+weight+gain+during+chemotherapy+and+outcomes+in+patients+with+advanced+non%E2%80%90small+cell+lung+cancer&rft.jtitle=Journal+of+cachexia%2C+sarcopenia+and+muscle&rft.au=Roeland%2C+Eric+J.&rft.au=Fintelmann%2C+Florian+J.&rft.au=Hilton%2C+Fiona&rft.au=Yang%2C+Ruoyong&rft.date=2024-06-01&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=2190-5991&rft.eissn=2190-6009&rft.volume=15&rft.issue=3&rft.spage=1030&rft.epage=1040&rft_id=info:doi/10.1002%2Fjcsm.13426&rft_id=info%3Apmid%2F38468440&rft.externalDocID=PMC11154746 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2190-5991&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2190-5991&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2190-5991&client=summon |